NEW YORK, May 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRA, AVXL, BOXL, FCEL, and UPWK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sel…
NEW YORK (AP) — Anavex Life Sciences Corp. (AVXL) on Thursday reported a loss of $7.2 million in its fiscal second quarter.
Anavex Life Sciences Corp. (NASDAQ: AVXL) gained 40 cents, or 9.4%, to $4.65 on 2.3 million shares Wednesday, nearly 3x its average volume. On Monday and Tuesday the biopharmaceutical company's president and CEO presented a company update and participated in a panel at the 2020 BIO CEO & Investor Conference in New York. Luna Innovations Incorporated (NASDAQ: LUNA) rose 46 cents to $9.04 on higher-than- usual volume of 392,700 shares Wednesday.
Q2 2020 Anavex Life Sciences Corp Earnings Call
NEW YORK, May 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRA, AVXL, BOXL, FCEL, and UPWK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sel…
NEW YORK, May 05, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
The luxury market is likely to contract 20-35 percent this year, as the COVID-19 pandemic has shut down the world and brought business across luxury sectors to a halt, according to an updated Bain & Company report.
NEW YORK, NY / ACCESSWIRE / February 6, 2020 / Anavex Life Sciences Corp. (NASDAQ:AVXL) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on February 6, 2020 ...
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
NEW YORK, May 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATRA, AVXL, BOXL, FCEL, and UPWK. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by sel…
Kadmon goes up on positive data.Anavex proceeds with early stage trial.Entera down on poor interim data.
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, will hold its Annual Meeting of Shareholders (Annual Meeting) on Tuesday, April 7, 2020 at 10:00 a.m. ET. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease.
NEW YORK, Feb. 04, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
NEW YORK, May 07, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
In the latest trading session, Anavex Life Sciences (AVXL) closed at $2.62, marking a -0.38% move from the previous day.
Q1 2020 Anavex Life Sciences Corp Earnings Call
Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
NEW YORK, Feb. 06, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Thursday reported a loss of $7.2 million in its fiscal second quarter. The New York-based company said it had a loss of 12 cents per share. The results exceeded Wall Street expectations. The average est…
Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.
Anavex Life Sciences (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Published in Journal of Neuroimmunology, Results Highlight ANAVEX®2-73 (blarcamesine) Shown to Protect and Repair Myelin Forming Cells ANAVEX®2-73 (blarcamesine) Provides.
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today provided an update on the evolving COVID-19 condition and the Company’s response to its clinical program development. Anavex’s paramount obligation is to ensure the safety of all participants in its clinical programs and the integrity of the studies in which they participate.
NEW YORK, May 21, 2020 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated.
Published in Alzheimer's & Dementia Journal, Results Highlight ANAVEX®2-73 (blarcamesine) Clinical Study, the First Reported Genome-Wide Search for Biomarkers Associated.
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ANAVEX®2-73 (blarcamesine) clinical development program for the treatment of Rett syndrome.
As of late, it has definitely been a great time to be an investor Anavex Life Sciences Corp.